newsfilter
← Latest News
Business Wire·

KalVista Pharmaceuticals Provides Operational Update and Fiscal Year 2025 Financial Results

– Received FDA approval of EKTERLY® (sebetralstat)—the first and only oral on-demand treatment for hereditary angioedema; U.S. launch underway – – Six additional global regulatory submissions under review – –